Michael Coyle Psychologist Medicare: Accepting Medicare Assignments Practice Location: 5 A Sunset Avenue, Putnam, CT 06260 Phone: 860-928-2119 Fax: 860-928-4079 |
Dr. Wayne David Rosenfield, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 320 Pomfret St, Day Kimball Healthcare, Putnam, CT 06260 Phone: 860-963-6385 Fax: 860-963-6393 |
Dawn Gurn, LPC Psychologist Medicare: Not Enrolled in Medicare Practice Location: 112 Main Street, Suite #9, Putnam, CT 06260 Phone: 860-963-3807 |
Dr. Paul D Williams, PH D Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 5 Prospect St, Putnam, CT 06260 Phone: 860-928-5904 Fax: 860-928-0701 |
Andrea T Coyle Psychologist Medicare: Accepting Medicare Assignments Practice Location: 5a Sunset Ave., Putnam, CT 06260 Phone: 860-928-2119 Fax: 860-928-4079 |
Mr. Joel David Perlmutter, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 158 Main St., Suite #12, Putnam, CT 06260 Phone: 860-928-6619 Fax: 978-897-9797 |
News Archive
Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs.
In research published today by Nature, an international team describes the finest map of changes to the structure of human genomes and a resource they have developed for researchers worldwide to look at the role of these changes in human disease.
Today's headlines detail the Obama administration announcement that it would delay the health law rule requiring businesses provide insurance to workers.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry recently completed another successful showcase of its Unified eClinical Solution at the annual DIA show. DATATRAK's premier Solution coupled with the DATATRAK ONE business model are hallmarks of its singular technological vision and unwavering commitment to customers.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 6 days ago